The Toxicity of T-DM1 in Breast Cancer Patients with Liver Metastases
1 Views
administrator
07/03/23
Mark D. Pegram, MD, a professor of medicine at Stanford University Medical Center and the director of the Breast Cancer Program at the Stanford Cancer Institute, discusses the results of a retrospective analysis that examined the toxicity of patients with liver metastases that were enrolled in phase III studies of T-DM1 for metastatic breast cancer.
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
-
Category
Show more
Facebook Comments
No comments found